SIH Partners’s Arbutus Biopharma ABUS Stock Holding History

SIH Partners’s Portfolio ABUS Stock Details ABUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-12,318	Closed	-$43K	–	161
2025 Q1	$43K	Buy	+12,318	New	+$41.1K	﹤0.01%	255

Other funds holding ABUS

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

WCM

Whitefort Capital Management New York $339M AUM 52.48% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

TSC

Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

BCP

BlackBarn Capital Partners New York $1.24B AUM 55.98% 1-Year Est. Return

SIH Partners's ABUS Position: Q2 2025 in Review

SIH Partners sold out of Arbutus Biopharma (ABUS) in Q2 2025, closing a stake of 12,318 shares — an estimated $43K sold.

SIH Partners first reported a position in ABUS in Q1 2025 and held it in 1 quarter. The position peaked at $43K in Q1 2025. 162 funds tracked by Wall St. Rank hold ABUS as of Q2 2025.

SIH Partners reported no remaining Arbutus Biopharma position as of Q2 2025 after selling out during the quarter.
SIH Partners sold 12,318 Arbutus Biopharma shares in Q2 2025, an estimated $43K.
SIH Partners first reported a position in Arbutus Biopharma in Q1 2025 and held it in 1 quarter.
SIH Partners's Arbutus Biopharma position peaked at $43K in Q1 2025.
162 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q2 2025.

Based on SIH Partners's 13F filing for Q2 2025, filed 14 Aug 2025.